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Neonatal diabetes mellitus (NDM) is an extremely
rare entity with a reported incidence of one in
400,000–500,000 live births. It is usually diagnosed
within the first 3 months of life and persists for > 2
weeks [1,2]. NDM is characterized by significant
hyperglycemia requiring insulin therapy, combined
with low levels of insulin for the first 6–8 weeks of
life. NDM can be life-threatening if not diagnosed
promptly. There are two main types of NDM, perma-
nent (PNDM) and transient NDM (TNDM) [3]. In-
trauterine growth retardation, failure to thrive, fever,
dehydration, hyperglycemia and acidosis, with or
without ketonuria, are the clinical features of the dis-
ease. Kir6.2 (encoded by the KCNJ11 gene) is the pore-
forming subunit of the beta-cell ATP-sensitive K+
channel (KATP) and belongs to the inwardly-rectifying
potassium channel family. The high prevalence of
Kir6.2 mutations in PNDM means that all children
< 6 months of age diagnosed with diabetes should be
tested for such mutations at diagnosis. Detection of a
Kir6.2 mutation offers the possibility of discontinu-
ing insulin and starting sulfonylurea, while main-
taining good glycemic control [4,5]. The aim of this
Received: Nov 20, 2008 Accepted: Jun 9, 2009
Address correspondence and reprint requests to:
Dr P. Savida, Department of Pediatrics, Institute
of Child Health, Government Medical College,
Kottayam, Kerala, India.
E-mail: savidap@yahoo.com
CLINICAL PROFILE AND ETIOLOGY OF
DIABETES MELLITUS WITH ONSET AT
LESS THAN 6 MONTHS OF AGE
Joseph J. Valamparampil, Shibi Chirakkarot, P. Savida, and S. Omana
Department of Pediatrics, Institute of Child Health, Government Medical College, Kottayam, Kerala, India.
The aim of this study was to determine the clinical profile and etiology of diabetes mellitus (DM)
with onset at < 6 months of age. All children aged < 6 months diagnosed with DM at a tertiary
referral center between 2005 and 2008 were included in the study. Three cases of DM with onset
at < 6 months of age were identified. All patients were female and of the same ethnic origin, with
nonconsanguineous parents. Intrauterine growth retardation was noted in all three patients, and
diabetic ketoacidosis and hypertriglyceridemia in two of the three. Blood samples from all three
patients and their parents were analyzed for mutations in the KCNJ11 gene (inwardly-rectifying
potassium channel, subfamily J, member 11 gene; OMIM 600937). A heterozygous de novo muta-
tion in the KCNJ11 gene was detected in one patient, which confirmed the diagnosis of perma-
nent neonatal DM. Neither C-peptide secretion nor circulating islet cell antibodies were detected
in any patient during diagnosis, but C-peptide elevation was detected in the patient with perma-
nent neonatal DM after treatment with sulfonylurea. One infant had clinical and immunological
evidence of congenital cytomegalovirus infection while the diabetes in another case was postulated
to be syndromic. DM within the first 6 months of life is a rare condition with various etiologies.
The high prevalence of Kir6.2 mutations in neonatal diabetes means that all children < 6 months
of age diagnosed with diabetes should be tested for Kir6.2 mutations at diagnosis.
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study was to determine the clinical profile and prob-
able etiology of diabetes mellitus (DM) with an onset
age of < 6 months at a tertiary referral center.
METHODS
Patients
All the children with onset of DM at < 6 months of
age included in this study were Indians. They were
treated and regularly followed-up at the Department
of Pediatrics, Government Medical College,
Kottayam, Kerala, India, which is a tertiary hospital.
The clinical profiles of the children with onset of DM
at < 6 months of age who presented to our hospital
between 2005 and 2008 were analyzed. DM was diag-
nosed according to WHO criteria [1]. The date of the
first insulin injection was taken as the date of diagno-
sis. All the children with PNDM were treated with a
standard insulin schedule combining intermediate-
and short-acting human insulin preparations, once or
twice a day, as required. Growth and the degree of
clinical and biochemical control were prospectively
assessed periodically in all children.
Laboratory tests
The following investigations were carried out during
the initial presentation and admission using standard
laboratory methods: venous blood gas analysis,
serum concentrations of glucose, triglycerides, elec-
trolytes, urea, and creatinine. Blood was screened for
the presence of IgG and IgM antibodies against
Toxoplasma, cytomegalovirus (CMV), and rubella,
Coxsackie, and herpes viruses. Plasma C-peptide
concentration was estimated by radioimmunoassay.
Mutation analysis
Blood samples from patients and their parents were
analyzed for mutation in the KCNJ11 gene. Following
DNA extraction, the single exon of the KCNJ11 gene
was amplified by polymerase chain reaction (PCR) in
three overlapping fragments. Successful amplifica-
tion was confirmed by agarose gel electrophoresis,
which allowed visualization of the PCR products.
Purified PCR products were sequenced using the
dideoxy chain termination sequencing method. The
products of the sequencing reactions were then 
separated by size using a capillary sequencer. DNA
sequences were generated using computer software,
depicted as electropherograms and then analyzed.
This analysis was performed at the Molecular
Genetics Laboratory at Royal Devon & Exeter NHS
Foundation Trust in Exeter, UK. One DNA sample
from a child with dysmorphic features was se-
quenced for several additional candidate genes,
including ATP-binding cassette, subfamily C, mem-
ber 8 (ABCC8; OMIM 600509, encoding SUR1, one of
two essential subunits of the KATP channel), insulin
(INS; OMIM 176730), and neurogenic differentiation
1 (NEUROD1; OMIM 601724).
RESULTS
Three children < 6 months of age were diagnosed
with DM during the study period, including two
cases in 2007 and one in 2006. One case has been
reported previously. None of the children were the
products of consanguineous marriages. However,
the prevalences of insulin-dependent DM (IDDM)
and non-insulin-dependent DM (NIDDM) among
their relatives were high. The mothers of two of the
children had gestational diabetes. The paternal and
maternal grandfathers and the maternal grand-
mother of one child, and the maternal grandmother
of another had NIDDM, while two cousins had
IDDM. The age at onset of the first symptoms ranged
from 45 days to 4.5 months. The duration of symp-
toms reported by parents prior to diagnosis ranged
from 2 to 4 days. The presenting symptoms were: fever
(2/3), lethargy and poor feeding (2/3), polyuria (1/3),
vomiting (2/3), cough (1/3), breathlessness (2/3), irri-
tability (1/3), and poor cry (1/3). The baseline char-
acteristics of the study children are shown in Table 1.
None of the children were within the age group
usually presenting with DM, so a clinical diagnosis of
hyperglycemia was not considered. All patients were
female and of the same ethnic origin. Severe oligohy-
dramnios was detected during the antenatal period
in one child. The birth weights ranged from 0.95 to
2.3 kg, and all the infants had intrauterine growth
retardation. One child had no dysmorphic features.
One child had microcephaly, dysmorphic facies,
bilateral cataract, bilateral congenital glaucoma with
secondary optic atrophy, clinodactyly, one café-
au-lait spot on her chest and hypertonia of all four
limbs. The third infant had bilateral cataract, bilateral
congenital talipes equinovarus, microcephaly and
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hepatosplenomegaly. Laboratory results at presenta-
tion are shown in Table 2.
Blood glucose concentrations were not related to
the age of onset or to the duration of symptoms. One
child showed no signs of ketoacidosis, while the other
two had clinical and laboratory evidence of severe
ketosis. Mild-to-moderate ketonuria was detected in
two of the three patients, with a pH <7.0. Serum
triglyceride concentrations were significantly elevated
in two of the infants. Electrolyte abnormalities in-
cluded hyponatremia (serum Na+ < 130 mmol/L) in
two cases, with resulting seizures in one child, while
hyperkalemia (serum K+ > 5.5 mmol/L) was seen in
only one child. Two of the children had normal renal
function tests, while one presented with diabetic
ketoacidosis and acute renal failure and was treated
with insulin, intravenous fluids, antibiotics and peri-
toneal dialysis, after which her renal function
improved rapidly. There were histories of clinically
significant viral illnesses during pregnancy in two of
the mothers, and antibodies against CMV (IgM and
IgG classes) were detected in one patient at presenta-
tion. Islet cell antibodies were not detected in any of
the three infants at presentation.
Abdominal ultrasonography results were normal in
all the children. Computed tomography of the head in
the child with dysmorphic features showed widely
separated and parallel ventricles, suggestive of corpus
callosal agenesis (Figure 1), and echocardiography
revealed a small ventricular septal defect. There was no
clinical or laboratory evidence of diabetes insipidus,
while the results of a brain stem evoked response
audiometry study suggested bilateral sensorineural
deafness. This child developed septicemia at 4 months
of age and died. The mean insulin requirement after
diagnosis was 1 U/kg/day. None of the patients
showed evidence of complete or partial remission.
Blood samples from all the patients and their par-
ents were analyzed for mutation in the KCNJ11 gene.
The DNA sample from the child with dysmorphic
features was sequenced for several additional candi-
date genes, including ABCC8, INS and NEUROD1,
but no mutations were detected. A heterozygous
R201C mutation in the KCNJ11 gene (Figure 2) was
detected in one child at 4.5 months old. This result
confirmed a diagnosis of PNDM due to a mutation in
the Kir6.2 subunit of the KATP channel. Her parents
were negative for the mutation, suggesting that it
was a de novo mutation in the infant.
The patient was treated with oral glibenclamide
(as a powder dissolved in water) at 0.6 mg/kg/day,
increased over the next 4 days to 1 mg/kg/day, while
insulin was concomitantly tapered off. At the end of
the transfer period, her serum C-peptide level was
0.26 ng/L, showing an eight-fold increase over that
seen during insulin therapy alone. This indicated
increased endogenous insulin release. The blood glu-
cose limit was set between 140 and 220 mg/dL to
avoid episodes of hypoglycemia. However, her blood
glucose level failed to reach the target with gliben-
clamide alone, and insulin therapy was restarted, but
at a lower dose of 0.6 U/kg (previous dose, 2 U/kg).
Over the next few weeks, her blood sugar levels sta-
bilized and reached an average of around 198 mg/dL,
with reduced variations from the normal range. In-
sulin was later gradually withdrawn. The patient
continued to take oral glibenclamide (1 mg/kg/day).
She remained asymptomatic, and was found to be
gaining weight and showing normal neurodevelop-
mental progress at follow-up.
DISCUSSION
NDM is an extremely rare entity with a reported inci-
dence of one in 400,000–500,000 live births. It is usually
diagnosed within the first 3 months of life, and per-
sists for > 2 weeks. It is usually a single gene disorder
Table 1. Baseline characteristics of the children diagnosed with diabetes mellitus at < 6 months of age
At birth At presentation
Case no. Gestational 
Weight (kg) Length (cm) HC (cm) Age (d)
Duration of 
Weight (kg) Anomalies
age (wk) symptoms (d)
1 38 2.3 50 33 60 3 3.5 Nil
2 37 2.2 48 34 156 4 5.5 Present
3 32 0.950 40 27 45 3 1.1 Present
HC = head circumference.
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associated with altered beta-cell number and func-
tion. The period of diagnosis is variable, with various
sources describing periods from 1 to 3 months [1–4].
NDM is characterized by significant hyper-
glycemia requiring exogenous insulin therapy, com-
bined with low levels of insulin in the first 6–8 weeks
of life. NDM can be life-threatening if not diagnosed
promptly. Of the two main types of NDM, TNDM
accounts for about 50–65% of cases of NDM, resolves
by a median of 12 weeks, and is usually associated
with abnormalities of chromosome 6, including pa-
ternal uniparental disomy and paternal duplications
of 6q24, with loss of imprinting and an increased risk
of diabetes later in life [3,5].
A genetic diagnosis is possible in 97% of patients
diagnosed with TNDM. Mutations of the KATP chan-
nel genes, ABCC8 and KCNJ11, account for the 
majority (89%) of non-6q24 TNDM [6]. Transient and
permanent DM need to be differentiated from the
transient hyperglycemia seen in neonates receiving
parenteral glucose infusion, and those with sep-
ticemia and central nervous system disorders. All of
our patients were otherwise healthy, receiving no
parenteral nutrition, and sepsis markers were nega-
tive at the time of diagnosis [7].
There are no clinical features or laboratory 
parameters that can be used to predict if a neonate
with DM will eventually develop permanent or tran-
sient disease. However, some patients with the 
permanent form do not have intrauterine growth
retardation, which is universally seen in the transient
6q phenotype, and exocrine pancreatic dysfunction is
more commonly associated with PNDM than with
Lateral ventricles
spaced apart & parallel
Figure 1. Computed tomography of the head showing brain
anomalies (arrows).
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TNDM. Diagnosis can be confirmed by genetic
analysis [5].
Intrauterine growth retardation, failure to thrive,
fever, dehydration, hyperglycemia, and acidosis with
or without ketonuria are the clinical features of the
disease. All the patients reported here had intrauter-
ine growth retardation [5,7]. PNDM is defined as
hyperglycemia diagnosed within the first 3 months
of life and requires insulin therapy for life [6]. Muta-
tion in the gene encoding Kir6.2, the pore-forming
subunit of KATP, is the most common cause of PNDM
[8]. There is a spectrum of phenotypes associated
with activating mutations in Kir6.2, the mildest phe-
notype being caused by mutation in the KCNJ11 gene,
the commonest of which is R201H [3,6,9].
The identification of an ABCC8 or KCNJ11 muta-
tion in a patient with hyperinsulinism or NDM is
important, as it provides a definitive diagnosis of
their disorder and also confirms the subtype. This
information can help to predict the likely course of
the disease and can also direct the clinical manage-
ment of the patient. KATP channels that are insensitive
to adenosine triphosphate as a consequence of Kir6.2
mutations can still be closed by sulfonylureas and
glinides that bind to the sulfonylurea receptor 1 sub-
unit and thus close the channel directly. Sulfonylureas
can therefore be considered as an alternative to
insulin injections. However, these patients require
high doses of sulfonylurea; 0.4–1.0 mg/kg gliben-
clamide, compared with a maximum suggested dose
of 0.33 mg/kg in adults. Most patients with Kir6.2
mutations present with symptomatic hyperglycemia
with a median glucose concentration of 33.5 mmol/L,
and ketoacidosis is also present in many cases. The
majority of patients have lower birth weights
(median, 2.58 kg), with 71% below the 10th centile for
gestational age [3,6,8,10].
Our patient with an R201C mutation fits the clini-
cal profile described above. She had a low birth
weight and presented around 2 months of age with
diabetic ketoacidosis and a blood sugar level of
33.66 mmol/L. Her ketoacidosis was rapidly con-
trolled with insulin, but her blood sugar levels varied
widely and were not normalized despite very high
doses of insulin. After initiation of glibenclamide,
together with low-dose insulin, her blood glucose
levels normalized and there was a rise in endogenous
insulin secretion.
We postulated that intrauterine infection was
responsible for the development of DM in the second
case. Human CMV has been reported to induce the
production of islet cell autoantibodies that react
specifically with a 38-kDa islet cell protein, which
may represent islet cell-specific antigens in a propor-
tion of CMV-associated DM cases. These observa-
tions suggest that the association of diabetes with
Coxsackie B viruses might be due to cytolytic infec-
tion of the beta cells, with no link to autoimmunity,
while both rubella virus and CMV are probably asso-
ciated with autoimmune IDDM [11]. To date, rubella
is the only virus for which conclusive evidence has
demonstrated a link between infection and increased
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Figure 2. The results of direct sequencing of the KCNJ11 gene. Upper panel, normal control; lower panel, patient with heterozygous
R201C (c.601C > T) mutation.
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risk of developing IDDM, with variable time of
onset. The very early onset of DM in this patient was
unusual for a case of intrauterine infection [12].
The third case had several unusual features,
including microcephaly, dysmorphic facies, bilateral
cataract, bilateral congenital glaucoma with second-
ary optic atrophy, clinodactyly, one café-au-lait spot
on her chest, hypertonia of all four limbs, corpus cal-
losal agenesis, partial lissencephaly, ventricular sep-
tal defect and bilateral sensorineural deafness [4].
These features are suggestive of one of the congenital
syndromes associated with PNDM, such as pancreas
agenesis, IPEX syndrome, or Wolcott-Rallison syn-
drome, which should be considered when evaluating
a neonate or young infant with PNDM. However, 
the absence of specific signs/symptoms and normal
abdominal sonography make these diagnoses un-
likely in this case [5,13]. Mitochondrial disease should
also be suspected whenever DM is associated with
sensorineural hearing loss, though the onset of dia-
betes in these cases is usually during adolescence or
adulthood, effectively ruling out the possibility in
this case [4,13].
Wolfram syndrome, or DIDMOAD syndrome, can
also be associated with DM and sensorineural hearing
loss with diabetes insipidus and optic atrophy. There
have been no recorded cases of NDM in Wolfram syn-
drome, and the optic atrophy in our case was second-
ary to glaucoma, making this an unlikely etiology.
Recent reports suggested that PNDM in a neonate
associated with sensorineural hearing loss, hypothy-
roidism, bilateral cataracts and dysmorphic disorder,
which do not fall within a known syndromic pattern
[4,7]. Our case demonstrated all these features, except
for hypothyroidism. The possibility that these two
cases represent a new, undescribed syndrome needs
to be considered.
A large Italian study of early-onset diabetes sug-
gested that diagnosis by 6 months represented the
boundary between non-autoimmune and type 1 dia-
betes. Consistent with this idea, no Kir6.2 mutations
were detected in 101 patients with insulin-treated dia-
betes diagnosed between 6 and 24 months of age. This
suggests that screening for Kir6.2 mutations is appro-
priate in all patients diagnosed before 6 months, but
not in patients diagnosed later than this [3].
The high prevalence of Kir6.2 mutations in
PNDM suggests that all children < 6 months of age
diagnosed with diabetes should be tested for Kir6.2
mutations at diagnosis and assessed for neurological
features. Detection of a mutation offers the possibil-
ity of discontinuing insulin and starting sulfony-
lurea, while maintaining good glycemic control.
There was only one case of PNDM in this series, 
who underwent successful transfer to sulfonylurea.
Treatment with sulfonylurea may also limit neuro-
logical damage, even when it is unable to control dia-
betes. Those patients with NDM lacking Kir6.2
mutations provide an excellent resource for genetic
studies aimed at identifying novel genes involved in
insulin secretion [3,6,8].
To conclude, DM within the first 6 months of life
is a rare condition that should be considered in sick
infants with unexplained hyperglycemia, because a
missed diagnosis can prove to be fatal. The high
prevalence of Kir6.2 mutations in PNDM means that
all children < 6 months of age diagnosed with dia-
betes should be tested for Kir6.2 mutations at diagno-
sis and assessed for neurological features. The
majority of such cases are of the transient type, which
can be managed with insulin therapy or oral hypo-
glycemic agents.
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